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The disruption in blood supply due to myocardial infarction is a critical determinant for infarct
size and subsequent deterioration in function. The identification of factors that enhance
cardiac repair by the restoration of the vascular network is, therefore, of great significance.
Here, we show that the transcription factor Zinc finger E-box-binding homeobox 2 (ZEB2) is
increased in stressed cardiomyocytes and induces a cardioprotective cross-talk between
cardiomyocytes and endothelial cells to enhance angiogenesis after ischemia. Single-cell
sequencing indicates ZEB2 to be enriched in injured cardiomyocytes. Cardiomyocyte-specific
deletion of ZEB2 results in impaired cardiac contractility and infarct healing post-myocardial
infarction (post-MI), while cardiomyocyte-specific ZEB2 overexpression improves cardio-
myocyte survival and cardiac function. We identified Thymosin β4 (TMSB4) and Prothy-
mosin α (PTMA) as main paracrine factors released from cardiomyocytes to stimulate
angiogenesis by enhancing endothelial cell migration, and whose regulation is validated in our
in vivo models. Therapeutic delivery of ZEB2 to cardiomyocytes in the infarcted heart induces
the expression of TMSB4 and PTMA, which enhances angiogenesis and prevents cardiac
dysfunction. These findings reveal ZEB2 as a beneficial factor during ischemic injury, which
may hold promise for the identification of new therapies.
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In the Western world, heart failure has the highest mortalityand morbidity rates of all diseases1. Ischemic heart disease iscaused by the occlusion of a coronary artery, which results in
hypoxia-induced loss of cardiomyocytes. The loss of viable
myocardium initially induces the activation of fibroblasts
required for proper scar formation in the infarcted area. Secon-
darily to the injury, the remote myocardium undergoes a
pathological remodeling response, characterized by cardiomyo-
cyte hypertrophy and further extracellular matrix (ECM)
deposition, which can ultimately lead to heart failure and death.
Despite the therapeutic benefits of current treatment options for
ischemic heart disease, the prevalence continues to increase every
year2. Therefore, it remains of great importance to gain a better
understanding of the mechanisms underlying cardiac remodeling
and repair to develop novel and improved therapeutic strategies.
Single-cell sequencing (SCS) has become an attractive tool to
study detailed gene expression differences within individual cells
in the setting of their local environment. We recently developed a
new method to perform SCS in adult cardiac tissue and applied it
to healthy and injured hearts. In doing so, we were able to obtain
gene expression profiles in specific cell populations coming from
the diseased hearts which allowed us to identify novel factors
involved in pathological cardiac remodeling3.
By applying SCS on murine cardiac tissue from both control
and injured hearts, we uncovered the DNA-binding transcription
factor ZEB2 to be induced in cardiomyocytes that originated
predominantly from the injured heart. While ZEB2 has been
broadly studied for its role in epithelial to mesenchymal transi-
tion4 and cellular (de)differentiation5,6, so far, its function in
cardiomyocyte biology was unknown. Here we show by gain- and
loss-of-function studies that ZEB2 confers cardioprotective effects
after ischemia via an increase in circulating levels of TMSB4 and
PTMA7–9. In line with these findings, the therapeutic delivery of
ZEB2 to cardiomyocytes is able to recapitulate these protective
effects after MI. These data suggest that the increase of ZEB2 in
cardiomyocytes in response to stress protects the heart from
ischemic damage via cell non-autonomous effects, which may
hold great promise for future heart failure therapies.
Results
ZEB2 is expressed in injured cardiomyocytes. To define novel
mechanisms underlying cardiac remodeling and repair after
ischemic injury, we subjected mice to either MI or sham surgery
(n= 3) and collected tissue for single-cell analysis (Fig. 1a–b),
applying our method described previously3. Using the SORT-Seq
protocol10,11, we obtained the cellular gene expression profiles
and detected on average 24,840 transcripts from 2,768 genes per
cell. After filtering procedures and quality control measures, we
retained a total number of 1186 cells for subsequent analysis (465
from sham and 721 from 3 days post-MI (3 dpMI). K-medoids
clustering of 1-Pearson correlation showed that based on gene
expression similarities, these cells could be clustered in 14 dif-
ferent cell populations (Fig. 1c and Supplementary Fig. 1a). Using
the expression of well-established marker genes, we were able to
identify all main cardiac cell types, such as cardiomyocytes,
fibroblasts, endothelial cells, and immune cells (Fig. 1c, Supple-
mentary Fig. 1b-g and Supplementary Data 1).
Since cardiomyocytes are critical regulators of cardiac remo-
deling and repair12, we decided to focus our analysis on this cell
type. Clustering analysis performed only on cardiomyocytes
showed that cells originating from sham or injured hearts, for the
most part, clustered separately (Fig. 1d), indicating diversity in
global gene expression. To explore the biological function of the
differentially regulated genes, we subjected enriched genes from
injured cardiomyocytes (log2 fold change > 6, p < 0,001, n= 263
genes) to the PANTHER Classification System13. Among others,
the enriched genes appeared to encode for cytoskeletal proteins,
enzyme modulators, or transcription factors (TFs) (Fig. 1e,
Supplementary Data 2). As TFs are potent regulators of gene
expression, we set out to explore their functional relevance in
more detail. Among the 11 genes known to encode for TFs, we
identified Zinc Finger E-box Binding Homeobox2 (ZEB2)
(Fig. 1e), which has previously been described to have a role in
epithelial to mesenchymal transition and cellular dedifferentia-
tion14. Our data indicated ZEB2 to be specifically increased in
cardiomyocytes coming from the injured heart (Fig. 1f). Immu-
nofluorescence indicated ZEB2 to be expressed in several cardiac
cell types, including macrophages, immune cells, and injured
cardiomyocytes flanking the infarcted region (Fig. 1g). Also, in
patients suffering from ischemic heart disease, ZEB2 expression
could be confirmed in a portion of cardiomyocytes, while we were
unable to detect a signal in the control human heart (Fig. 1h).
Zeb2 deletion from cardiomyocytes impairs cardiac function
and repair after MI. To study the function of ZEB2 in cardio-
myocytes, we generated cardiomyocyte-specific Zeb2 knockout
mice (Zeb2 cKO) (Supplementary Fig. 2a). QPCR analysis indi-
cated approximately a 50% reduction in cardiac Zeb2 expression
levels in Zeb2 cKO mice compared to control (Zeb2 fl/fl) (Sup-
plementary Fig. 2b). Under baseline conditions deleting Zeb2
from cardiomyocytes did not appear to induce any gross mor-
phological or functional changes (Supplementary Table 1, and
Fig. 2c–g).
Since we found ZEB2 to be upregulated in cardiomyocytes after
ischemic stress, we next subjected adult Zeb2 fl/fl and Zeb2 cKO
mice to sham or MI surgery and collected tissue 14 days later
(Fig. 2a). Loss of ZEB2 exclusively from cardiomyocytes was
confirmed by qPCR and immunofluorescence (Fig. 2b, c).
Compared to the Zeb2 fl/fl mice, Zeb2 cKO mice experienced a
greater cardiac dysfunction as measured by fractional shortening
(FS) and a non-significant increase in left ventricular internal
diameter in systole (LVIDs) post-MI (Fig. 2d, e, Supplementary
Fig. 3a and Supplementary Table 2). We also observed an increase
in infarct size in Zeb2 cKO compared with Zeb2 fl/fl mice,
assessed by the percentage of the infarcted area of the total LV
circumference (Supplementary Fig. 3b-c). These findings were
corroborated by histological analysis showing a dilated infarcted
region in the Zeb2 cKO mice compared to controls (Fig. 2f). In
line with the observed detrimental consequences of ZEB2 removal
from cardiomyocytes, we observed a decrease in the expression of
the pro-survival marker BCL-XL after ischemic injury in Zeb2
cKO mice compared to controls (Fig. 2g–h). Additionally,
cardiomyocytes in the remote area displayed a hypertrophic
response due to Zeb2 deletion, as indicated by WGA staining
(Fig. 2i–j). Ischemia-induced heart failure is a consequence of
impaired perfusion of the heart, and new blood vessel formation
is a critical component of wound healing.15 We observed a
significant reduction in the endothelial markers Pecam1 and
Vegf1 in the infarcted Zeb2 cKO hearts when compared to Zeb2
fl/fl controls (Fig. 2k–l), which corresponded with an overall
decrease in the percentage of PECAM1 positive vessels in the
remote and border zone (Fig. 2m–p). A decrease in capillary
density and expression of endothelial markers was also observed
in Zeb2 cKO mice after sham, implying a vascular difference at
baseline (Supplementary Fig. 3d–j). Together, these data indicate
that Zeb2 inhibition in cardiomyocytes impairs cardiac function
and promotes pathological remodeling after ischemic injury.
To start exploring the role of ZEB2 in the injured heart in more
detail, we performed RNA-seq on cardiac tissue from Zeb2 fl/fl
and Zeb2 cKO mice subjected to MI. In doing so, we found 2339
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Fig. 1 ZEB2 is expressed in injured cardiomyocytes. a Study design. b Area of the heart subjected to single-cell sequencing. c-d t-SNE map indicating
transcriptome similarities among all individual cells. c Different numbers and colors highlight different clusters identified by K-medoids clustering. d Colors
highlight the conditions of the hearts from which the cells were derived (sham in green and 3 dpMI in pink). e The PANTHER Classification System analysis
on enriched genes from injured cardiomyocytes when compared to sham. f t-SNE map showing the expression of Zeb2 across all cardiomyocytes from
sham and 3 dpMI hearts. g Representative confocal images from sham and ischemic mouse hearts 3 dpMI stained for ZEB2, ACTN2, and DAPI. h
Representative confocal images from human control and ischemic hearts stained for ZEB2, ACTN2, and DAPI. Expression is depicted as normalized
transcript count on a color-coded scale. t-SNE indicates t-distributed stochastic neighbor embedding. White arrows show ZEB2 positive cardiomyocytes.
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(-0,2 Log2 fold change) downregulated and 1599 (0,2 Log2 fold
change) upregulated genes (Supplementary Fig. 4a and Supple-
mentary Data 3). The differential expression of the top regulated
genes could be confirmed by qPCR in a larger sample set (n= 7)
(Supplementary Fig. 4b-c). Pathway analysis showed that
upregulated genes were mainly linked to metabolic pathways
(Supplementary Fig. 4d), whereas downregulated genes were
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Fig. 2 Cardiomyocyte-specific deletion of Zeb2 impairs infarct healing. a Study design. b mRNA expression levels of Zeb2 in Zeb2 fl/fl and Zeb2 cKO mice
post-surgery. c Immunofluorescence for ZEB2, TNNT2, and DAPI of cardiac sections from Zeb2 fl/fl and Zeb2 cKO mice 14 dpMI. d–e Quantification of
d fractional shortening (FS) and e left ventricular internal diameter in systole (LVIDs) from Zeb2 fl/fl and Zeb2 cKO mice post-surgery. f Representative
images of cardiac four-chamber view (top panel), sections from infarcted areas stained with either H&E (second panel) or SR (third panel). g
Representative WB for BCL-XL in tissue from Zeb2 fl/fl and Zeb2 cKO 14 dpMI and h its quantification. i WGA staining to measure cardiomyocyte surface
area and j its quantification. k, l mRNA expression levels of k Pecam1 and l Vegf in Zeb2 fl/fl and Zeb2 cKO mice post-surgery. m, n Immunofluorescence for
PECAM1, TNNT2, and DAPI in m remote and n border zone. o, p quantification of PECAM1 positive blood vessel areas in histological sections of hearts
from Zeb2 fl/fl and Zeb2 cKO mice 14 dpMI in (m, n). Green dashed line indicates sham Zeb2 fl/fl control. H&E indicates Hematoxylin and Eosin, SR
indicates Sirius Red. White arrows show ZEB2 positive cardiomyocytes. White stars show ZEB2 negative cardiomyocytes. Data are represented as mean ±
SEM, *p < 0.05, **p < 0.01, ****p < 0.0001, each dot indicates a biological replicate, n is indicated in figures. Comparison of two groups was performed with
the unpaired, two-tailed Student’s t-test between Zeb2 cKO vs Zeb2 fl/fl post-MI (b, d, e, h, j, k, l, o, p). Source data are provided as a Source Data file.
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and regulation of actin cytoskeleton (Supplementary Fig. 4e),
suggesting a decline in cell survival and angiogenic response in
Zeb2 cKO hearts compared to wild type littermates16–19. This
overrepresentation of pathways involved in ECM and vasculature
maintenance indicated that deleting Zeb2 did not only affect
cardiomyocytes but also other cell types, suggesting a cell non-
autonomous function mediated by ZEB2 (Supplementary Fig. 4e).
ZEB2 promotes cross-talk between cardiomyocytes and other
cardiac cell types. Based on the cell non-autonomous effects
observed after ZEB2 deletion from cardiomyocytes, we set out to
determine whether ZEB2 might be regulating factors that are
released from injured cardiomyocytes. To this end, we inhibited
ZEB2 in hypoxic neonatal rat cardiomyocytes (NRCMs), after
which we collected the conditioned medium and added it on
either freshly cultured NRCMs or the non-cardiomyocyte fraction
of cells (non-CMs) from the same isolation (Supplementary
Fig. 5a). Subsequently, we collected RNA from both conditions
and measured the expression of ECM/fibrotic and endothelial
markers. We did not observe any significant differences in the
cardiomyocyte fraction when exposed to the conditioned medium
from treated cardiomyocytes (Supplementary Fig. 5b). However,
in using the same conditioned medium, the non-CMs cells did
show a decrease in ECM/fibrotic and endothelial genes (Supple-
mentary Fig. 5c).
To study the cellular effects of the conditioned medium in
more detail, we exposed both fibroblasts (NIH-3T3) and
endothelial cells (HUVECs) to medium from ZEB2-
overexpressing cardiomyocytes (H10) (Fig. 3a). To narrow our
focus, we fractionated the conditioned medium and screened for
the fraction that had the biggest effect on non-CMs populations
(Fig. 3b). Treating NIH-3T3 cells and HUVECs with the
conditioned medium showed no apparent effects on morphology
or activation. Conditioned medium of the ZEB2-overexpressing
cardiomyocytes containing the smaller proteins did however
induce an increase in endothelial cell migration (Fig. 3c–f) and
the expression of angiogenesis-related genes (Fig. 3g–h). Based on
these data, we performed mass spectrometry (MS) on the fraction
containing proteins of sizes between 3 and 30 kDa. Among the
proteins that were detected to be enriched in the supernatant of
the ZEB2-overexpressing cells, we identified 40 plasma proteins
based on the Human Protein Atlas database https://www.
proteinatlas.org/search. Since we were searching for factors
directly regulated by ZEB2, out of these 40 plasma proteins, we
selected genes that were found to be downregulated in the RNA-
seq dataset from the Zeb2 cKO hearts (n= 11) (Fig. 3i and
Supplementary Data 4). Overexpression or knockdown of Zeb2
(Fig. 3j–k), resulted in an increase or decrease of the 11 identified
factors, respectively (Fig. 3l–m), indicating a regulatory effect of
ZEB2 on the expression of these genes. Together these data
suggest that ZEB2 regulates the secretion of factors from
cardiomyocytes that directly affect endothelial cell migration.
Pro-angiogenic factors TMSB4 and PTMA are regulated by
ZEB2. To start exploring the direct effect of ZEB2 on these cir-
culating factors in vivo, we first set out to measure their expres-
sion levels in Zeb2 cKO mice subjected to MI. While the
expression of many factors did not change in Zeb2 cKO mice
post-MI, we observed a significant downregulation for Tmsb4,
Ptma, Rack1 and Dynll1 (Fig. 4a–b, Supplementary Fig. 6a–i).
Interestingly, Tmsb4 and Ptma are actively secreted factors that
have previously been associated with endothelial cell migration
and angiogenesis7,8,20. Immunofluorescence validated a reduction
of TMSB4 and PTMA protein in injured Zeb2 cKO hearts 14 days
post-MI (14 dpMI) (Fig. 4c–d). As we saw an induction of ZEB2
after ischemic injury in mice, we next measured whether this was
also true for Tmsb4 and Ptma. All three genes showed a tran-
scriptional activation post-MI with a peak in expression 3-7 days
after injury (Fig. 4e–g). This positive correlation between the
expression of ZEB2 and the TMSB2 and PTMA could also be
confirmed in cardiac samples from patients suffering from
ischemic heart disease (Fig. 4h–i), suggesting a conserved
mechanism. These data imply a possible regulation of Tmsb4 and
Ptma by ZEB2 most likely due to multiple ZEB2 binding sites
present in close proximity to the transcription starting site (TSS)
in Tmsb4 and Ptma in mouse and human (Supplementary
Fig. 6j). Additionally, we made use of existing ChIP-seq data
(https://www.encodeproject.org/targets/ZEB2-human/) and
identified ZEB2 binding motifs in enhancer regions of both
TMSB4 and PTMA (Supplementary Fig. 6k-l), indicating that
ZEB2 protein can directly bind to those enhancers causing an
increase in TMSB4 and PTMA expression.
TMSB4 and PTMA from cardiomyocytes drive endothelial cell
migration and proliferation. To examine the secretory and pro-
angiogenic effect of TMSB4 and PTMA from cardiomyocytes, we
infected human iPSC-derived cardiomyocytes with adeno-
associated viruses overexpressing either ZEB2, TMSB4 or
PTMA in the absence or presence of a siRNA targeting ZEB2 or a
control (Supplementary Fig. 7a). This resulted in an increase or
decrease in expression compared to control cells, as indicated by
qPCR analysis (Supplementary Fig. 7b-e). Conditioned medium
from cardiomyocytes overexpressing ZEB2, TMSB4 or PTMA
enhanced the migration of endothelial cells, with no apparent
additive effect when overexpressing both TMSB4 or PTMA
(Supplementary Fig. 7f-g). Conversely, exposing endothelial cells
to conditioned medium from iPSC-derived cardiomyocytes
treated with a siRNA against ZEB2, lowered endothelial cell
migration (Supplementary Fig. 7h-i). However, this inhibitory
effect could be rescued by the conditioned medium from
cardiomyocytes, where ZEB2 inhibition was followed by over-
expression of TMSB4 or PTMA (Supplementary Fig. 7h-i).
Additionally, we performed sprout formation and proliferation
assays to further validate the importance of ZEB2 in
different aspects of the angiogenic response. To this end, we
treated iPSC-derived cardiomyocytes with siRNA-control,
siRNA-ZEB2, siRNA-TMSB4, siRNA-PTMA and a combination
of siRNA-TMSB4 and siRNA-PTMA (Fig. 5a). Next, we collected
conditioned medium from treated cardiomyocytes and used it to
treat HUVECs (Fig. 5a). In doing so observed that ZEB2 inhi-
bition in cardiomyocytes resulted in a significant decrease in the
number of sprouts per spheroid and a non-significant decrease in
cumulative sprout length per spheroid (Fig. 5b–d). Inhibition of
TMSB4 and PTMA separately did not affect the number and
length of sprouts, but when inhibited together, it showed a
comparable effect as ZEB2 inhibition (Fig. 5b–d). We also ana-
lyzed endothelial cell proliferation and observed a significant
decrease in EdU positive nuclei when treated with conditioned
medium from ZEB2-inhibited cardiomyocytes (Fig. 5e–f). Even
though we did not reach significance in the decrease of EdU
positive HUVECs in TMSB4 and PTMA-treated conditions, we
did observe a very pronounced decrease in the expression of cell
cycle genes in all conditions (Fig. 5g–i). Conversely, when we
used conditioned medium from cardiomyocytes overexpressing
ZEB2, TMSB4, PTMA and a combination of TMSB4 and PTMA
(Fig. 6a), we observed that overexpression of ZEB2 in cardio-
myocytes increased sprout number and cumulative sprout length
per spheroid in the presence of VEGF (Fig. 6b–d). Conditioned
medium from TMSB4-expressing cardiomyocytes enhanced those
effects even without VEGF treatment (Fig. 6b–d). Additionally, all
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treatments were able to increase proliferation in HUVECs, as
indicated by EdU incorporation (Fig. 6e–f).
These findings support the notion that ZEB2 mediates
endothelial cell migration and proliferation, at least partially via
the secretion of TMSB4 or PTMA from cardiomyocytes.
Genetic overexpression of ZEB2 protects the heart from
ischemic damage and promotes an angiogenic response. Based
on the detrimental phenotype observed after ZEB2 removal from
cardiomyocytes, we generated cardiomyocyte-specific ZEB2
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LoxSTOPLox-ZEB2 mice21 with mice overexpressing Cre
recombinase under the control of the cardiac-specific α-myosin
heavy chain promoter (αMHC-Cre Tg)22 (Supplementary Fig. 8a-
b). Overexpression of Zeb2 was confirmed by qPCR for Zeb2 (and
eGFP) (Supplementary Fig. 8c-d). Compared to WT littermates,
we did not observe any morphological or functional effects of
ZEB2 overexpression under baseline conditions (Supplementary
Fig. 8e–g and Supplementary Table 3).
To study the function of ZEB2 overexpression during an
ischemic event, we subjected Zeb2 cTg mice to MI for 14 days,
after which we performed functional and molecular analyses
(Fig. 7a). Zeb2 cTg-based overexpression was confirmed on
mRNA (Fig. 7b–c) and protein level (Fig. 7d, Supplementary
Fig. 9a). Echocardiography showed an improvement in cardiac
function (FS), a decline in left ventricular internal diameter
(LVIDs), and smaller infarct size in mice overexpressing ZEB2 in
cardiomyocytes (Fig. 7e–f, Supplementary Fig. 9b–d and Supple-
mentary Table 4). This was confirmed by histology showing better
maintenance of cardiac morphology of the infarcted region in the
Zeb2 cTg mice with a reduction in the fibrotic response (Fig. 7g).
Contrary to the observations made in the Zeb2 cKO mice, we
detected a significant increase in Tmsb4 and Ptma in response to
Fig. 3 Mass spectrometry to identify ZEB2 targets. a Experimental setup. b Fractionation strategy of conditioned medium for mass spectrometry
purposes. c-d Representative images of scratch assay in HUVECs treated with the indicated conditioned media at 0 and 20 hours after treatment. e-f
Quantification of wound closure from (c-d). g-h mRNA expression levels of Vegfr1, Vegfr2, Fgf2, and Notch1 in HUVECs after treatment with conditioned
medium. i Pie charts showing numbers of proteins identified by mass spectrometry in fraction 3-30 kDa. j ZEB2 overexpression in H10 cells and k ZEB2
inhibition in NRCMs. l-m Validation of mRNA expression of genes encoding for the 11 selected proteins identified by mass spectrometry in (I). Green
dashed line indicates corresponding control. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, each dot indicates a biological replicate, n is
indicated in figures. Comparison of two groups was performed with the unpaired, two-tailed Student’s t-test compared to the control indicated as green
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Fig. 4 Tmsb4 and Ptma as ZEB2 target genes. a-b mRNA expression levels of a Tmsb4 and b Ptma in Zeb2 fl/fl and Zeb2 cKO mice post-surgery. c-d
Immunofluorescence for c TMSB4, ACTN2, and DAPI and d PTMA, ACTN2, and DAPI of histological sections of hearts from Zeb2 fl/fl and Zeb2 cKO mice
14 dpMI. e-g mRNA expression levels of e Zeb2, f Tmsb4, and g Ptma in mice subjected to MI for different time periods. h-i 1-Pearson correlation between
ZEB2 and h TMSB4 and i PTMA in human ischemic hearts. Green dashed line indicates sham Zeb2 fl/fl control. Data are represented as mean ± SEM, *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, each dot indicates a biological replicate, n is indicated in figures. Comparison of two groups was performed
with the unpaired, two-tailed Student’s t-test, between Zeb2 cKO vs Zeb2 fl/fl post-MI (a, b) and between sham vs MI at different time points (e, f, g).
Source data are provided as a Source Data file.
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ZEB2 overexpression (Fig. 7h–k). This corresponded with an
increase in Pecam1 at both the mRNA and protein levels
(Fig. 7l–n) and an overall increase in the PECAM1 positive area
in the Zeb2 cTg hearts in the remote and border zone (Fig. 7o–p).
Additionally, we already observed a mild increase in capillary
density and endothelial markers under sham conditions, which
can potentially contribute to the enhanced angiogenesis post-MI
(Supplementary Fig. 9e-k). In line with the protective con-
sequences of overexpressing ZEB2 in cardiomyocytes, we
observed an increase in the expression of the pro-survival gene
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Fig. 5 Knock-down of ZEB2, TMSB4, and PTMA in cardiomyocytes inhibits endothelial cell migration and proliferation. a Experimental setup. b
Representative images of sprouts formed by HUVECs upon treatment indicated in (a). c Quantification of sprouts number per spheroid. d Quantification of
cumulative sprout length per spheroid. Data in b-d is from one experiment with 4-12 biological replicates. e Representative immunofluorescent images of
HUVECs treated as indicated in (a), nuclei stained for DAPI and EdU. f Quantification of EdU positive nuclei. g-i mRNA expression levels of g Mki67, h Pcna i
Cdk4 in HUVECs treated with conditioned medium from (a). Data are represented as mean ± SEM, each dot indicates a biological replicate, n is indicated in
figures. Data were analyzed by ordinary one-way ANOVA with Dunnett’s multiple comparison test (c, d, f, g, h, i). Source data are provided as a Source Data file.
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BCL-XL in Zeb2 cTg mice post-MI (Supplementary Fig. 9l-m).
This corresponded to a reduction in cardiomyocyte hypertrophy
in the remote area of the Zeb2 cTg hearts, as indicated by WGA
staining (Fig. 7q–r).
Together these data demonstrated that transgenic overexpres-
sion of ZEB2 in cardiomyocytes induces a cardioprotective
response due to an improved angiogenesis post-MI.
AAV9-mediated ZEB2 delivery is therapeutically beneficial. To
explore the increase in ZEB2 in a therapeutically relevant manner,
we made use of AAV9-mediated gene transfer, previously
reported to be a useful tool for local delivery to cardiomyocytes.23
We generated AAV9-control and AAV9-Zeb2 (Supplementary
Fig. 10a) and tested different routes of delivery, including intra-
peritoneal (IP) injection into mouse pups, and intracardiac (IC)
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Fig. 6 Overexpression of ZEB2, TMSB4, and PTMA in cardiomyocytes enhances endothelial cell migration and proliferation. a Experimental setup.
b Representative images of sprouts formed by HUVECs upon treatment indicated in (a). c Quantification of sprouts number per spheroid. d Quantification
of cumulative sprout length per spheroid. Data in b-d is from one experiment with 4-12 biological replicates. e Representative immunofluorescent images of
HUVECs treated as indicated in (a), nuclei stained for DAPI and EdU. f Quantification of EdU positive nuclei. Data are represented as mean ± SEM, *p <
0.05, **p < 0.01, ***p < 0.001, each dot indicates a biological replicate, n is indicated in figures. Data were analyzed by ordinary one-way ANOVA with
Dunnett’s multiple comparison test (f) and with two-way ANOVA with Sidak’s multiple comparison test (c, d). Source data are provided as a Source
Data file.
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and intravenous (IV) injection into adult mice (Supplementary
Fig. 10b–d). Since intracardiac injection resulted in the strongest
increase in expression of Zeb2 in the heart (Supplementary
Fig. 10c), we used this method for our subsequent experiments.
To test the therapeutic benefit of intracardiac delivery of ZEB2,
we injected male C57BL/6 J mice immediately after sham or MI
surgery with AAV9-control or AAV9-Zeb2 and performed the
analysis 14 and 28 days later (Fig. 8a). ZEB2 expression was
confirmed to be increased at both times points post-injection
(Fig. 8b–d and Supplementary Fig. 11a–c). Increasing ZEB2 in
cardiomyocytes improved cardiac function and morphology after
MI at both time points as measured by FS and LVID (Fig. 8e–f
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and Supplementary Fig. 11d-e, Supplementary Table 5, Supple-
mentary Table 6). We detected a significant increase in Tmsb4
and Ptma levels in response to ZEB2 delivery (Fig. 8g–j and
Supplementary Fig. 11f–i). This corresponded with an increase in
Pecam1 and Vegf expression (Fig. 8k–m and Supplementary
Fig. 11j–l) and an overall increase in the PECAM1 positive area in
Zeb2 cTg hearts (Fig. 8n and Supplementary Fig. 11m).
Additionally, when increasing ZEB2, we observed a trend in
elevated levels of the pro-survival gene BCL-XL 28 days post- MI
(Fig. 8o–p) and smaller cardiomyocyte size in the remote area as
indicated by WGA staining (Fig. 8q–r and Supplementary
Fig. 11n-o). Our data suggest that the therapeutic delivery of
ZEB2 stimulates cardiomyocyte-derived angiogenic signals in the
injured heart and thereby contributes to improved cardiac repair
and cardiac function (Fig. 9).
Discussion
Heart disease continues to be the leading cause of death world-
wide, due to limited therapeutic options and the heart’s inability
to regenerate healthy cardiomyocytes after myocardial infarction.
Discovery of players involved in myocardial repair after ischemia
could serve in the development of enhanced therapeutic
interventions.
Here we use single-cell sequencing to show that ZEB2 is
expressed in injured cardiomyocytes, where it functions as a
cardioprotective factor involved in infarct healing and cardiac
repair in a non-autonomous manner. ZEB2 expression was
increased in the heart only during the first days after MI, the time
when endogenous repair response takes place, and before a
fibrotic scar is being produced24. Constitutive expression of
ZEB2, as well as its therapeutic delivery to the injured heart,
triggered a subsequent increase in vessel density resulting in
diminished scar formation and preserved cardiac function. Our
data demonstrate the importance of cardiomyocyte signaling after
ischemic injury and, for the first time, show the importance of
ZEB2 during cardiac repair.
While ZEB2 as a transcription factor is well known for its
functions in EMT and development4,25, it has only been shown to
function in a cell non-autonomous manner in brain cortex
development26. This study demonstrated that ZEB2 regulates the
production of signaling factors in post-mitotic neurons, which
feedback to progenitors to influence the timing of cell fate switch
and the number of neurons and glial cells throughout
corticogenesis26.
Cardiac cell populations interact with each other not only by
physical contact, receptor-ligand interactions, or cell adhesion
complexes, but also via a variety of soluble paracrine, autocrine,
and endocrine factors27. Secreted proteins are required to main-
tain normal cardiac function and control pathological remodeling
of the myocardium in response to injury. Our data show that
ZEB2 expression in cardiomyocytes induces the expression and
secretion of factors involved in cardiac remodeling post-MI. Mass
spectrometry on conditioned medium from cardiomyocyte-like
cells overexpressing ZEB2 revealed an increase in circulating
levels of TMSB4 and PTMA, which have already been linked to
cardioprotection by regulating neovascularisation8, angiogen-
esis28, and apoptosis29, and could explain the observed in vivo
phenotype. TMSB4 treatment is already being used to promote
wound repair in skin, cornea, and heart in a series of ongoing
clinical trials30. In the heart, studies have shown that
TMSB4 stimulates the formation of new cardiomyocytes, which
originate from the epicardial layer31, and promotes neovascu-
larization32. Additionally, TMSB4 has been shown to play anti-
inflammatory, antioxidant, and antifibrotic effects during liver
injury in mice33. On the other hand, PTMA has been shown to
stimulate cardiac endothelial cell migration, angiogenesis, and
wound healing20. It has also been recently proven to protect from
retinal ischemic damage34. Here we showed that both TMSB4 and
PTMA are transcriptionally regulated by ZEB2 in injured cardi-
omyocytes and are subsequently secreted to promote downstream
protective signaling. Recent reports on ZEB2 also suggested that it
promotes cell survival and angiogenesis in cancer35, which is in
line with the biological functions we observed in the injured
heart.
Our results present ZEB2 as a promising mediator of angio-
genic signals coming from cardiomyocytes in response to injury.
Although genetic deletion and overexpression of ZEB2 in cardi-
omyocytes have minor effects on capillary density under baseline
conditions, therapeutic delivery of ZEB2 post-injury is sufficient
to restore cardiac function by stimulating angiogenesis, which in
turn improves cardiac repair. Targeted delivery using a
cardiomyocyte-specific promoter would further improve the
specificity of the therapy and allow for a more directed treatment
in order to prevent undesired effects in other organs. Although
follow-up studies will have to provide more detailed insights into
the exact mechanisms, both the identification of ZEB2 and its
downstream signals offer potential new therapeutic opportunities
for patients suffering from ischemic heart disease.
Methods
Mice. All mouse studies were conducted in accordance with protocols approved by
the ethics committee of the Hubrecht Institute in Utrecht. Mice were housed in a
normal condition with 12:12 h light: dark cycle in a temperature-controlled room
with food and water ad libitum. For all animal experiments, we used 8–9 weeks old
male mice.
Myocardial infarction (MI) and transthoracic echocardiography (echo). Myocardial
infarction or sham surgery was performed in C57BL/6 J wild type mice (Figs. 1 and
7), Zeb2 fl/fl and Zeb2 cKO mice (Fig. 2), Zeb2 WT and Zeb2 cTg (Fig. 6) (8-
10 weeks of age) by permanent ligation of the left anterior descending artery (LAD)
for 3 days (Fig. 1 and corresponding Supplementary figures), 14 days (Figs. 2, 6 and
corresponding Supplementary figures) or 28 days (Fig. 7 and corresponding Sup-
plementary figures). In brief, mice were anesthetized with a mixture of ketamine
and xylazine by IP injection, and hair was shaved from the thorax. A tracheal tube
Fig. 7 Genetic overexpression of ZEB2 protects the heart from ischemic damage. a Study design. b-c mRNA expression level of b Zeb2, c eGFP (CT
values) in Zeb2 WT and Zeb2 cTg mice post-surgery. d Immunofluorescence for ZEB2, TNNT2 and DAPI of histological sections of hearts from Zeb2 WT
and Zeb2 cTg mice 14 dpMI. e-f Quantification of e fractional shortening (FS) and f left ventricular internal diameter in systole (LVIDs) from Zeb2 WT and
Zeb2 cTg mice post-surgery. g Representative images of cardiac four-chamber view (top panel) and sections of infarcted areas stained with H&E (second
panel) or SR (third panel). h, i mRNA and j, k protein expression levels of Tmsb4 and Ptma in Zeb2 WT and Zeb2 cTg mice post-surgery. l-m
Immunofluorescence for PECAM1, TNNT2, and DAPI in l remote and m border zone in hearts from Zeb2 WT and Zeb2 cTg mice post-MI. n mRNA
expression levels of Pecam1 in hearts from Zeb2 WT and Zeb2 cTg mice post-surgery. o-p quantification of PECAM1 positive blood vessel area in
histological sections from (l-m). q WGA staining to measure cardiomyocyte surface area and r its quantification. Green dashed line indicates sham Zeb2
WT control. H&E indicates Hematoxylin and Eosin, SR indicates Sirius Red. White arrows show ZEB2 positive cardiomyocytes. Data are represented as
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, each dot indicates a biological replicate, n is indicated in figures. Comparison of two groups was performed
with the unpaired, two-tailed Student’s t-test between Zeb2 cTg vs Zeb2 WT post-MI (b, c, e, f, h, i, n, o, p, r). Source data are provided as a Source
Data file.
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was placed and the mouse was connected to a ventilator (UNO Microventilator
UMV-03, Uno BV.). The surgical site was cleaned with iodine and 70% ethanol.
Using aseptic technique with sterile instruments the skin was incised of the midline
to allow access to the left third intercostal space. Pectoral muscles were retracted
and the intercostal muscles were cut caudal to the third rib. Wound hooks were
placed to allow access to the heart. The pericardium was incised longitudinally and
the left anterior descending coronary artery (LAD) identified. A 7.0 silk suture was
placed around the LAD. Successful ligation of the coronary artery was definite by
whitening of the heart anterior wall. After the surgery, the rib cage was closed with
5.0 silk suture, and the skin closed with a wound clip. The animal was disconnected
from the ventilator, the tracheal tube removed, and placed on a nose cone with
100% oxygen. To alleviate pain or discomfort after the surgery, mice were injected
with 0.05–0.1 mg/kg of Buprenorphine. During the whole procedure and recovery
period animals were placed on a 38 °C hot plate. Cardiac function was evaluated by
C57BL/6J
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two-dimensional transthoracic echocardiography on sedated, adult mice (2% iso-
flurane) using a Visual Sonic Ultrasound system with a 30MHz transducer
(VisualSonics Inc., Toronto, Canada). The heart was imaged in a parasternal long-
axis as well as short-axis view at the level of the papillary muscles, to record M-
mode measurements, determine heart rate, wall thickness, and end-diastolic and
end-systolic dimensions. Fractional shortening (defined as the end-diastolic
dimension minus the end-systolic dimension normalized for the end-diastolic
dimension) as well as ejection fraction (defined as the stroke volume normalized
for the end-diastolic volume), were used as an index of cardiac contractile function.
Of note, MI surgeries were performed by two different animal surgeons and the
severity of the MI differs between studies, however the comparison is always
performed within the studies.
Digestion of the heart and single-cell sorting. Single-cell experiments were per-
formed as described previously1. In short, mice (3 days post sham or post-MI) were
euthanized and hearts were perfused with cold perfusion buffer (135 mM NaCl,
4 mM KCl, 1 mM MgCl2, 10 mM HEPES, 0.33 mM NaH2PO4,10 mM glucose,
10 mM 2,3-butanedione monoxime (Sigma, St Louis, MO), 5 mM taurine (Sigma),
adjust pH to 7.2 at 37 °C. The infarcted area of the heart (infarct and border zone)
or the corresponding region of sham hearts (n= 3 per condition) were collected
and minced into small pieces using a scalpel and transferred into a glass vial with
1.5 ml of cold digestion buffer (0.5 mg/ml Liberase TL (Roche, #5401020001),
20μg/ml DNase I (Worthington, LK003172), 1 M HEPES, Dulbecco’s Modified
Eagle Medium (DMEM), high glucose, GlutaMAX™ Supplement, pyruvate (Gibco,
#31966021)). Tissues were digested in a shaking (100 rpm) 37 °C water bath for
15 min. The obtained cell suspension was pipetted up and down and transferred
onto a 100 μm cell strainer and used for subsequent single-cell sorting. Cells were
collected into a 384-well plate format using flow cytometry FACS Aria II BD
bioscience). We applied multiple scatter properties to make sure we were sorting
for living and single cells.
Single-cell sequencing. The SORT-seq procedure was applied as before2. Cells were
sorted into 384 well plats containing 5μl of VaporLock oil and aqueous solution of
100 nl containing reverse transcriptase (RT) primers, Spike-in RNA molecules,
dinucleotide triphosphates (dNTP), and CELL-seq primers which consisted of a 24
bp polyT sequence followed by a 6 bp unique molecular identifier (UMI), a cell-
specific barcode, the 5’Illumina TrueSeq2 adapter, and T7 promoter sequence. 384
well plates containing cells and the above-mentioned reagents were incubated for 5
min at 65 °C, after which cDNA libraries were obtained by dispersion of the RT
enzyme and second strand mixes with the Nanodrop II liquid handling platform
(GC biotech). cDNA libraries in all wells were pooled, followed by separation of the
aqueous phase from the oil phase prior to in vitro transcription for linear ampli-
fication as performed by overnight incubation at 37 °C. Next Illumina sequencing
libraries were prepared using the TruSeqsmall RNA primers (Illumina) and
sequenced paired-end at 75-bp read length with Illumina NextSeq. The paired-end
reads obtained by Illumina sequencing were mapped with BWA-ALN3 to the
reference genome GRCm38/mm10 downloaded from the UCSC genome browser.
We detected on average 24,840 raw unique reads per cell and did not observe any
bi- or multimodal distribution of reads per cell, indicating that we indeed sorted
exclusively single cells. For quantification of transcripts abundance, the number of
transcripts containing unique molecular identifiers per cell-specific barcode was
counted for each gene. K-medoids clustering was based on the RaceID2 algorithm
to visualize cell clusters using t-distributed stochastic neighbor embedding (t-SNE)
and to compute genes up- or downregulated in all cells within the cluster compared
with cells not in the cluster4,5. Of note, all read counts for mitochondrial genes
were discarded due to the high abundance of transcripts coming from these genes
in cardiomyocytes, which interfered with downstream clustering.
Pathway analysis and gene ontology. The PANTHER Classification System6 was
used in order to categorize the gene expression signature of healthy vs. injured
cardiomyocytes based on protein class (Fig. 1). To investigate whether genes shared
a similar biological function, we searched for overrepresentation in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway and gene ontology (GO)
biological processes database using DAVID7. Significant enrichment of genes in
KEGG and GO terms are shown, p values are corrected for multiple testing using
the Benjamini-Hochberg method.
Heart collection for histological analysis. Adult hearts were excised from anesthe-
tized animals, washed in cold PBS, and fixed with 4% formalin at room tem-
perature (RT), embedded in paraffin, and sectioned at 4 μm. Paraffin sections were
stained with Hematoxylin and Eosin (H&E) for routine histological analysis and
Sirius Red (SR) for the detection of collagen according to standard procedures.
Slides were visualized using a Zeiss Axioskop 2Plus with an AxioCamHRc and
DM4000.
Human heart samples. Approval for studies on human tissue samples was obtained
from the Medical Ethics Committee of the University Medical Center Utrecht, The
Netherlands (12#387). Written informed consent was obtained or in certain cases
waived by the ethics committee when obtaining informed consent was not possible
due to the death of the patient. None of the co-authors was involved in tissue
collection. Tissue samples were anonymized before the access was obtained. In this
study, we included tissue from the left ventricular free wall of patients with end-
stage heart failure secondary to ischemic heart disease. The end-stage heart failure
tissue was obtained during heart transplantation or at autopsy. For immunohis-
tochemistry, samples from three patients were included from which the border
zone of the infarcted hearts was used to verify the localization of ZEB2 in hypoxic
cells. qPCR analysis for ZEB2, TMSB4, and PTMA was done on 30 tissue samples
from the left ventricular free wall of patients with ischemic heart disease (ischemic
Fig. 8 AAV9-mediated ZEB2 cardiac delivery improves infarct healing and cardiac function 28 dpMI. a Study design. b-c Expression levels of b
exogenous Zeb2 (CT values) and c Zeb2 mRNA in AAV9-control and AAV9-Zeb2 treated mice post-surgery. d Immunofluorescence for ZEB2, TNNT2 and
DAPI of histological sections of hearts from AAV9-control and AAV9-Zeb2 treated mice 28 dpMI. e-f Quantification of e fractional shortening (FS) and f
left ventricular internal diameter in systole (LVIDs) from AAV9-control and AAV9-Zeb2 treated mice post-surgery. g-h mRNA expression levels of g
Tmsb4 and h Ptma in hearts from AAV9-control and AAV9-Zeb2 treated mice 28 dpMI. i-k Immunofluorescence for i TMSB4, j PTMA and k PECAM1,
TNNT2 and DAPI of histological sections of hearts from AAV9-control and AAV9-Zeb2 treated mice 28 dpMI. l-mmRNA expression levels of l Vegf andm
Pecam1 in hearts from AAV9-control and AAV9-Zeb2 treated mice 28 dpMI. n Quantification of PECAM1 positive blood vessel areas in histological
sections of hearts from AAV9-control and AAV9-Zeb2 treated mice 28 dpMI. o Representative WB for BCL-XL in tissue from AAV9-control and AAV9-
Zeb2 treated mice 28 dpMI and p its quantification. q WGA staining to measure cardiomyocyte surface area and r its quantification. Green dashed line
indicates sham AAV9-control. White arrows show ZEB2 positive cardiomyocytes. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, each dot indicates a biological replicate, n is indicated in figures. Comparison of two groups was performed with the unpaired, two-tailed
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Fig. 9 ZEB2 expression in injured cardiomyocytes promotes angiogenic
signaling. Model depicting the activation of ZEB2 in injured
cardiomyocytes, resulting in transcriptional activation of Tmsb4 and Ptma
followed by their secretion from cardiomyocytes subsequently enhancing
the angiogenic response.
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region, border zone, and remote region) and 5 samples coming from the left
ventricular free wall of the healthy donor.
Immunohistochemistry. Immunohistochemistry was performed on paraffin-
embedded heart sections. After deparaffinization, rehydration, heat-induced anti-
gen retrieval, and blocking with 0.05% BSA, sections were incubated with primary
antibodies overnight at 4 °C. Subsequently, sections were washed and incubated
with secondary antibodies for 1 h at RT followed by DAPI 1:5000 (Invitrogen,
#D3571) for 10 min at RT. Sections were then washed and mounted with ProLong
Gold Antifade Mountant (Invitrogen, #P36934). Antibodies used in this study
include mouse anti-ACTN2 (Sigma, #A7732), rabbit anti-ACTN2 (Sigma,
#HPA008315), mouse anti-TNNT2 (Abcam, #ab8295), rabbit anti-ZEB2 (Novus-
bio, #NBP1-77179), rabbit anti-TMSB4 (Immundiagnostik AG, #A9520), goat anti-
PTMA (Novusbio, #NBP1-36979) and goat anti-PECAM1 (R&D Systems,
#abAF3628). We used a corresponding secondary fluorescent antibody Alexa Fluor
488 donkey anti-mouse IgG (H+ L) (Invitrogen, #A21202), Alexa Fluor 488
donkey anti-goat IgG (H+ L) (Invitrogen, #A11055), Alexa Fluor donkey anti-
rabbit IgG (H+ L) (Invitrogen, #A10037), Alexa Fluor 568 donkey anti-mouse IgG
(H+ L) (Invitrogen, #A21206), Alexa Fluor 568 donkey anti-rabbit IgG (H+ L)
(Invitrogen, #A10042). FITC-labeled wheat-germ-agglutinin (WGA) (Sigma-
Aldrich, #L4895) was used to visualize and quantify cardiomyocyte cross-sectional
area with ImageJ software. Blood vessels were stained with PECAM1 and the
percentage of the PECAM1+ areas was calculated using ImageJ software.
Immunohistochemistry was also performed on H10 cells transfected with Zeb2
overexpressing vector and siRNA against Zeb2 (as described in detail below). Cells
were fixed with 4%PFA, quenched with NH4Cl, permeabilized, blocked with 1%
fish gelatin (Gelatin from cold-water fish skin, Sigma-Aldrich, #G7765), and
incubated with mouse rabbit anti-ZEB2 antibody (Novusbio, #NBP1-77179) for 25
min at RT prior to incubation with the corresponding secondary Alexa Fluor 488
donkey anti-mouse IgG (H+ L) (Invitrogen, #A21202), 20 min at RT. The cells
were washed and sealed with a mounting medium (ProLong Gold Antifade
Mountant with DAPI, Invitrogen, #P36935). EdU was visualized with the Click-iT
EdU Cell Proliferation Imaging Kit, Alexa Fluor 647, ThermoFisher, #C10340,
according to the instructions. Images were taken using the Leica TCS SPE confocal
microscope.
Genetic mouse models. Mice harboring a floxed allele of Zeb2 (Zeb2 fl/fl) were
already generated8 and crossed with mice harboring a Cre recombinase under the
control of the murine Myh6 promoter (αMHC-Cre Tg mice)9 to generate Cre-Zeb2
fl/fl (Zeb2 cKO) mice. Rosa26-LoxStopLoxZeb210 were crossed to αMHC-Cre Tg
mice to generate αMHC-Cre R26-lslZeb2/lslZeb2 (Zeb2 cTg) mice. Adult mice (8-
10 weeks of age) were used for baseline and MI studies. All mice were genotyped by
PCR using primers shown in Supplementary Table 7. All animal studies were
performed in accordance with local institutional guidelines and regulations. The
sample size was determined by a power calculation based upon an echocardio-
graphic effect size. Animal technicians blinded investigators to group allocation
during the experiment and when assessing the outcome.
RNA isolation and quantitative PCR. Total RNA was isolated from heart ventricles,
NRCMs, iPSC-derived cardiomyocytes, H10 cells, or HUVECs using TRIzol
reagent according to the manufacturer’s instructions. Total RNA (1 μg) was used
for mRNA-based reverse transcription using an iScript cDNA Synthesis Kit (Bio-
Rad, #1708891). QPCR was performed according to the SYBRgreen based meth-
odology using iQ SYBR Green Supermix (Bio-Rad, #170-8885). Transcript quan-
tities were normalized for endogenous loading. Primer sequences are provided in
Supplementary Table 7.
Western Blot and immunoprecipitation. Heart tissue lysates were produced in RIPA
buffer supplemented with Protease inhibitor cocktail (Roche, #11836170001).
Subsequently, samples were boiled in 4x Leammli buffer, including 2% β-
mercaptoethanol for 5 min at 99 °C. SDS-PAGE and Western Blotting was per-
formed using Mini-PROTEAN Tetra Vertical Electrophoresis Cell with Mini
Trans-Blot (Bio-Rad). Blotted membranes were blocked with 3–5% BSA in TBS-
Tween for 30 min at RT. Primary antibody incubation was performed overnight at
4 °C followed by an HRP-conjugated secondary antibody incubation for 1 h at RT.
After each antibody incubation, blots were washed 3×15 min with TBS-Tween.
Images were visualized using Clarity Western ECL Substrate (Bio-Rad, #170-5061)
and Amersham Imager 600. Stripping was performed using Mild stripping buffer
(1.5% glycine, 0.1% SDS, 1%Tween pH 2,2). Outputs were normalized for loading.
Antibodies used included rabbit anti-BCL-XL (Cell Signaling, #2764), mouse anti-
FLAG (Sigma, #F3165), mouse anti-GAPDH (Millipore, #MAB374). Peroxidase-
conjugated AffiniPure Rabbit Anti-Mouse IgG (H+ L) (Jackson ImmunoResearch,
#315-035-003), Peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+ L)
(Jackson ImmunoResearch, #111-035-003). Flag-tag pull-down was performed on
1mg of protein lysate from Zeb2 WT and Zeb2 cTg hearts after MI by using Anti-
FLAG Magnetic Beads (Sigma, #M8823). Pull down was performed by rotating the
proteins with Anti-FLAG beads at 4 °C overnight. The next day beads were washed
and proteins were eluted from beads using trippleFLAG elution buffer (Sigma,
#F4799) and used for western blot, as described above. Western blots were
quantified by ImageJ.
Bulk RNA sequencing. RNA sequencing was performed on heart tissue from Zeb2
fl/fl and Zeb2 cKO mice subjected to MI for 14 days. Total RNA was extracted from
the remote zone of hearts using TRIzol reagent as described above. RNA
sequencing libraries were prepared from non-ribosomal RNA using the TruSeq
Stranded Total RNA Library Prep Kit (Illumina) with Ribo-Zero according to the
manufacturer’s protocol. Next, strand-specific single-end 75 bp reads were gener-
ated on an Illumina NextSeq 500. Reads were aligned and quantified against the
Gencode.M4 gtf list for annotated genes using the STAR workflow. Heart libraries
were sequenced with a minimum of 14 million reads (16.2 ± 1.9 (mean ± sd)).
Differential expression was analyzed using DESeq v1.2211 using per condition
dispersion estimates.
Isolation of ventricular cardiomyocytes from neonatal rats. Cardiomyocytes were
isolated by enzymatic dissociation of 1-2-day-old neonatal rat hearts. In brief, pups
were placed on ice for 5–10 min for light anesthesia. After decapitation, hearts were
collected, ventricles were separated from atria and cut into small pieces in a
balanced salt solution prior to enzymatic digestion using trypsin (Thermo Fisher
Scientific, #15400054) under constant stirring at 37 °C. The supernatant, contain-
ing intact cardiomyocytes was collected, centrifuged at 300 g for 4 min, and
resuspended in Ham F10 medium (Thermo Fisher Scientific, #11550043) supple-
mented with 5% FBS, 10% L-glutamine, and 10% Pen-Strep. Collected cells were
seeded onto uncoated 100 mm plastic dishes for 1.5 h at 37 °C in 5% CO2 humi-
dified atmosphere. The supernatant, which consists mainly of CMs, was collected,
cells were counted and plated on gelatinized 6 well plates 1×106 cells per well. After
the 24 h medium was changed to Ham F10 supplemented with Insulin-Transferrin-
Sodium Selenite Supplement (Roche), 10% L-glutamine, and 10% Pen-Strep. Cells
were used for the hypoxia study and siRNA mediated ZEB2 knock-down.
Culturing and differentiation of iPSC cells towards cardiomyocytes. The
LUMC0020iCTRL06 human induced pluripotent stem cells (hiPSCs) were used to
generate cardiomyocytes using a defined medium with timed addition of growth
factors and small molecules13. hiPSCs were plated at a density of 50,000 cells/cm2
three days prior to differentiation to allow for attachment to Geltrex (Thermofisher
Scientific, A1413302) coated cell-culture plates. Differentiation was induced with
Cardio Differentiation Medium RPMI 1640 with HEPES and GlutaMax (Life
Technologies, #72400021), supplemented with Albumin (human recombinant,
Sigma-Aldrich, #A9731), L-Ascorbic Acid 2-phosphate (Sigma-Aldrich, #A8960)
with freshly added GSK3B-inhibitor CHIR99021 (Millipore, #361559). On day two,
the medium was replaced with Cardio Differentiation Medium supplemented with
Wnt-inhibitor IWP2 (Millipore, #681671). On day 4 and 6 the cells received a new
differentiation medium without additions. Finally, on day 8 (and every 2/3 days)
medium was refreshed with Cardio Culture Medium (RPMI 1640 with HEPES and
GlutaMax (Life Technologies, #72400021), supplemented with B27 with Insulin
(Life Technologies, #17504044). To enrich for cardiomyocytes, purification was
done for 4 days using selection medium (RPMI without D-glucose (Life Tech-
nologies, #11879020), supplemented with Albumin, L-Ascorbic Acid 2-phosphate,
and Sodium DL-lactate/HEPES buffer (Sigma, #L4263). Differentiation efficiency
was determined by flow cytometry for cardiac troponin T (cTNT) expression, using
an antibody directed to cTNT (Abcam, #ab45932). Cardiomyocytes were dis-
sociated after selection and reseeded in a density of 400,000 cells/cm2 on Geltrex
coated cell-culture plates.
Culturing H10 cells. H10 cells were cultured in DMEM with GlutaMAX (Thermo
Fisher, #10566016) supplemented with 10% FBS (Sigma-Aldrich, #F7524) and 1%
Pen-Strep (Thermo Fisher, #15070063). Cells were used for transfection with Zeb2
overexpressing vector and silencing of Zeb2 with siRNA.
siRNA transfection. For ZEB2 knock-down, we used Trilencer 27 (Origene,
#SR511798). siRNA transfection was performed in neonatal rat cardiomyocytes
(NRCMs), H10 cells, and iPSC-derived cardiomyocytes at a final concentration of
10 nM using Lipofectamine 2000 for NRCMs and H10 cells (Thermo Fisher Sci-
entific, #11668027) and Lipofectamine RNAiMAX (Thermo Fisher Scientific,
#13778030) for iPSC-derived cardiomyocytes for 24 h. Next, the medium was
refreshed for an additional 48 h, and cells were collected for analysis. Cells were
subjected to hypoxia (1%O2 and 5%CO2) for 6 h before collection (Supplementary
Fig. 6).
Production of conditioned media. NRCMs, H10 cells, or iPSC-derived cardio-
myocytes were cultured as described above and transfected with siRNA or AAV9
vectors for 24 h after which medium was refreshed and left for an additional 48 h.
After that conditioned medium was collected, filtered, and used to treat a new
batch of NRCMs and non-cardiomyocytes or HUVECs for 24 h.
HUVECs culturing and scratch assay. Human umbilical vein endothelial cells were
cultured in EBM-2 BulletKit medium (Lonza, #CC-3162). Scratches in cell
monolayers were generated with a 100 μL tip, washed with PBS, and incubated with
conditioned media. Cells were imaged at 0, 2, 5, and 20 h with Inverted Routine
Microscope ECLIPSE Ts2 (Nikon). The percentage of wound closure was measured
by ImageJ by calculating the percentage of area with cells vs total area. For
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proliferation assay, HUVECs were incubated with conditioned media for 48 h, EdU
treatment took place 24 h before the analysis.
Spheroid assay. Human umbilical vein endothelial cells (HUVECs) were trypsi-
nized and resuspended in ECM culture medium (Sciencell, USA) containing 0.6 gr/
L methylcellulose (Sigma). Cells were seeded (400 cells per well in 100 µl) in
U-bottom 96 well plates and cultured for 24 h at 37 °C and 5% CO2 to allow for the
formation of spheroids. The spheroids were collected and resuspended in FBS
(Sciencell) containing 2.4 gr/L methylcellulose and mixed 1:1 with collagen I
solution containing 3.77 g/L collagen I (Corning, USA), 10% M199 medium
(Sigma), 0.018 M HEPES, and 0.2 M NaOH to adjust pH to 7.4. The mixture with
the spheroids was allowed to polymerize for 30 min in a 24 well plate. A total of
100 µl of conditioned medium with or without VEGF (50 ng/mL) (Preprotech) was
added to the gels. Spheroids were visualized after 24 h using an Olympus IX50
microscope. The cumulative sprout length per spheroid was measured using
ImageJ software.
Mass spectrometry. H10 cells were plated into T75 flasks and transfected with
CMV-control or CMV-Zeb2 vector for 24 h. Medium was refreshed and left for an
additional 48 h. Subsequently, cells were collected for molecular analysis and
conditioned medium was collected to treat HUVECs and for mass spectrometry.
Conditioned medium was separated based on protein size (Centrifugal Filters,
Ultracel -3K and -30K, #Amicon Ultra, #UCF800324 and #UCF803024). Mass
spectrometry was performed on fraction 3–30kDa. For mass spectrometry; 2 M
Urea, 100 mM Tris-HCl, and 10 mM TCEP (end concentration) were added to the
supernatants. Samples were incubated at 56 °C for 30 min followed by adding 50
mM CAA and incubation of 5 min at RT. 0.2 µg Trypsin was added and incubated
overnight at 37 °C on a shaker. The following day, supernatants were concentrated
on zip-tip (C18), washed with 0.1% formic acid, and eluted with 80% acetonitile/
0.1% formic acid. Samples were vacuum concentrated, taken up in 0.1% formic
acid, and loaded on a 1.9 µm C18 column coupled to a Proxeon nano-LC system.
Samples were measured on the LTQ-Orbitrap Fusion Tribrid; Thermo Fisher
Scientific mass spectrometer, using a 200 min gradient and HCD fragmentation.
Raw files were analyzed with the Maxquant software version 1.5.2.8 (Cox and
Mann, 2008) oxidation of methionine set as variable modifications, and carbami-
domethylation of cysteine set as a fixed modification. The Rat protein database of
UniProt was searched with both the peptide as well as the protein false discovery
rate set to 1%.
AAV9 delivery to iPSC-derived cardiomyocytes. Adeno-associated viral vectors
(AAV, serotype 9) encoding ZEB2, TMSB4, PTMA, or empty vector were generated
in collaboration with Giacca lab in (Trieste, Italy). We used 5×103 viral genome
particles per cell to infect iPSC-derived cardiomyocytes.
Injection of AAV9 vectors. AAV9 viruses were generated as described above. First,
to assess the best way of delivery AAV9-control and AAV9-Zeb2 were injected via
three different routes into wild type mice. 0.5 × 1011 viral genome particles per
animal were injected into the myocardium of adult mice (two injections), using a
Hamilton syringe. 1×1011 viral genome particles per animal were injected intra-
venously into adult mice and intraperitoneally into 2 days old pups using an insulin
syringe with a 30-gauge needle. For the injury study, AAV9 intracardiac delivery
was performed in C57BL/6 J male mice from Charles River Laboratories (8 weeks
of age). Animals received sham or MI surgery as described above. AAV9-control
and AAV-Zeb2 virus at a dose of 0.5 × 1011 viral genome particles per animal were
injected as two intracardiac injections directly after LAD ligation, (2 × 15 μl
intracardiac injections in an area where the infarct will occur), using a Hamilton
syringe (31-gauge, 30° angle). The chest was closed as described above, and animals
were placed on 38 °C hot plate for the recovery period. To alleviate pain or dis-
comfort after the surgery, mice were injected with 0.05–0.1 mg/kg of Buprenor-
phine. Two and four weeks after the surgery and AAV9 injections, cardiac function
was analyzed by echocardiography, and hearts were collected for histological and
molecular analysis.
Statistical and reproducibility. The number of samples (n) used in each experiment
is indicated in the legends or shown in the figures and indicates biological repli-
cates. Results are presented as the mean ± standard error of the mean (SEM).
Statistical analyses were performed using PRISM (GraphPad Software Inc.
version 6). Two groups were statistically compared using the Student’s t-test.
Multiple groups were statistically compared with ordinary one-way ANOVA or
two-way ANOVA. Outliers were defined by Grubbs’ test (alpha= 0.05). Data are
represented as mean ± SEM. Differences were considered statistically significant at
p < 0.05. In the figures, asterisks indicate statistical significance (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001) which is also indicated in the individual
figures. All representative images of hearts or cells were selected from at least three
independent experiments with similar results unless indicated differently in the
figure legend.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the main data supporting the findings of this study are available
within the article and its Supplementary Information file. All sequencing data that
support the findings of this study have been deposited in the National Center for
Biotechnology Information Gene Expression Omnibus (GEO) and are accessible through
the GEO Series accession number GSE146285 (for SCS data) and GSE151638 (for Zeb2
cKO RNA-seq data). The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset
identifier PXD022212.
Source data are provided with this paper. Extra data are available from the
corresponding author upon request. Source data are provided with this paper.
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